18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomized, controlled clinical study
Open Access
- 15 January 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 28 (6) , 1337-1347
Abstract
The functional imaging technique of 18F‐fluoride positron emission tomography (18F‐PET) allows the noninvasive quantitative assessment of regional bone formation at any skeletal site, including the spine and hip. The aim of this study was to determine if 18F‐PET can be used as an early biomarker of treatment efficacy at the hip. Twenty‐seven treatment‐naive postmenopausal women with osteopenia were randomized to receive teriparatide and calcium and vitamin D (TPT group, n = 13) or calcium and vitamin D only (control group, n = 14). Subjects in the TPT group were treated with 20 µg/day teriparatide for 12 weeks. 18F‐PET scans of the proximal femur, pelvis, and lumbar spine were performed at baseline and 12 weeks. The plasma clearance of 18F‐fluoride to bone, Ki, a validated measurement of bone formation, was measured at four regions of the hip, lumbar spine, and pelvis. A significant increase in Ki was observed at all regions of interest (ROIs), including the total hip (+27%, p = 0.002), femoral neck (+25%, p = 0.040), hip trabecular ROI (+21%, p = 0.017), and hip cortical ROI (+51%, p = 0.001) in the TPT group. Significant increases in Ki in response to TPT were also observed at the lumbar spine (+18%, p = 0.001) and pelvis (+42%, p = 0.001). No significant changes in Ki were observed for the control group. Changes in BMD and bone turnover markers were consistent with previous trials of teriparatide. In conclusion, this is the first study to our knowledge to demonstrate that 18F‐PET can be used as an imaging biomarker for determining treatment efficacy at the hip as early as 12 weeks after initiation of therapy.Keywords
This publication has 40 references indexed in Scilit:
- The Precision and Sensitivity of18F-Fluoride PET for Measuring Regional Bone Metabolism: A Comparison of Quantification MethodsJournal of Nuclear Medicine, 2011
- The Epidemic of Hip Fractures: Are We on the Right Track?PLOS ONE, 2011
- Cortical bone: a target for fracture prevention?The Lancet, 2010
- Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional studyThe Lancet, 2010
- Hip Fractures and the Contribution of Cortical Versus Trabecular Bone to Femoral Neck StrengthJournal of Bone and Mineral Research, 2009
- Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A PerspectiveJournal of Bone and Mineral Research, 2008
- An update on biomarkers of bone turnover and their utility in biomedical research and clinical practiceEuropean Journal of Clinical Pharmacology, 2006
- Quantification of Skeletal Kinetic Indices in Paget's Disease Using Dynamic18F-Fluoride Positron Emission TomographyJournal of Bone and Mineral Research, 2002
- Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic ThresholdsOsteoporosis International, 2001
- Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometryThe Journal of Clinical Endocrinology & Metabolism, 1993